The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Ascentage Pharma
 
Employment - Next Oncology
Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors.
 
Anthony W. Tolcher
Employment - Next Oncology; START
Leadership - Symphogen
Consulting or Advisory Role - AbbVie (Inst); AbGenomics International (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Axiom Biotechnologies (Inst); Bayer (Inst); BioInvent (Inst); Boston Biomedical (Inst); Cello Health (Inst); EMD Serono (Inst); Forbius (Inst); Genentech/Roche (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunome (Inst); Immunome (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); OSI Pharmaceuticals (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Ridgeway Therapeutics (Inst); Scientex (Inst); Seagen (Inst); Sesen Bio (Inst); Seven and Eight Biopharmaceuticals (Inst); Symphogen (Inst); Syneos Health (Inst)
Research Funding - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Boehringer Ingelheim (Inst); CStone Pharmaceuticals (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Naturewise (Inst); NextCure (Inst); Nitto BioPharma (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
 
Raghad Karim
No Relationships to Disclose
 
Yuefen Tang
Employment - Ascentage Pharma
 
Hengbang Wang
Employment - Ascentage Pharma
 
Jiao Ji
No Relationships to Disclose
 
Jason Chen
Employment - Ascentage Pharma
 
Angela Kaiser
Employment - Ascentage Pharma
 
Piyush Sheladia
Employment - Ascentage Pharma
 
Mohammad Ahmad
Employment - Ascentage Pharma
 
ZHIYAN LIANG
Employment - Ascentage Pharma
 
Dajun Yang
Employment - Ascentage Pharma; Ascentage Pharma; Ascentage Pharma
Leadership - Ascentage Pharma; Ascentage Pharma; Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
Yifan Zhai
Employment - Ascentage Pharma; Ascentage Pharma; HealthQuest Pharma
Leadership - Ascentage Pharma; Ascentage Pharma; HealthQuest Pharma
Stock and Other Ownership Interests - Ascentage Pharma